Contents
Special Issue Topic

Immunotherapy in Cancer Patients

Guest Editor

Prof. Rossana Berardi E-Mail

Professor in Medical Oncology and Director of the Postgraduate School of Medical Oncology at Università Politecnica Marche; Director of Department of Medical Oncology, Director of “Genetic Cancer” Center and Breast Unit Coordinator at Ospedali Riuniti of Ancona, Italy

Research Keywords: Thoracic cancer; breast cancer; neuroendocrine tumors; innovative therapies; COVID-19 and cancer

About the Special lssue

Immunotherapy in the last years improved outcome of cancer patients, inducing durable tumour responses, in particular in patients affected by NSCLC and melanoma. Immune checkpoint inhibitors regulate and stimulate the immune system to recognize and attack tumour cells. It is commonly better tolerated than chemotherapy and targeted therapy with a unique toxicity profile depending on their different of mechanism of activity.
These toxicities, despite rare, can be sometimes disabling.
However, some patients do not benefit from immunotherapy. Several original researches investigated the potential predictive role of clinical, pathological, laboratoristic factors to select responder patients.
Notwithstanding, a validated predictive parameters do not detected.
Immunotoxicity could involve all organs and systems requiring a specific management including steroids, immunomodulating therapy in multidisciplinary approach. Pathophysiology of immune-toxicity is still unclear. Parameters potentially associated with increased risk of immune-related adverse events are still under investigation.
This special issue focus on predictive factors of response and toxicity in cancer patients treated with immunotherapy in order to improve the management of those subjects.

logo.pngWomen for Oncology – Italy supports this special issue.

Keywords: Immunotherapy; immune-related toxicity; multidisciplinary approach

Published Articles

Open Access Review
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
Stefano Cavalieri ... Laura D. Locati
Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:522–542
3826 103 7
Open Access Original Article
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
Edoardo Lenci ... Rossana Berardi
Published: June 28, 2021 Explor Target Antitumor Ther. 2021;2:227–239
3577 75 1
Open Access Review
Gastrointestinal disorders as immune-related adverse events
Daniele Balducci ... Luca Maroni
Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:174–186
3274 36 2
Open Access Review
Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
Valeria Cognigni ... Rossana Berardi
Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:122–138
7926 195 12
Open Access Review
Immunotherapy in gynecological cancers
Domenica Lorusso ... Giovanni Scambia
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:48–64
3442 46 5
Open Access Review
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
Luca Cantini ... Rossana Berardi
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:1–25
3766 37 0
Open Access Letter to the Editor
Is hyperprogressive disease a specific phenomenom of immunotherapy?
Marta Brambilla ... Mario Occhipinti
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427–433
3287 30 1
Open Access Review
An overview of immune checkpoint inhibitors in breast cancer
Federica Miglietta ... Nicla La Verde
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452–472
5017 115 6
Open Access Case Report
Pseudoprogression in lung cancer: a case report
Giulia Meoni ... Angela Stefania Ribecco
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372–380
4459 46 1